PMV Pharmaceuticals (PMVP)
(Real Time Quote from BATS)
$1.47 USD
-0.01 (-0.68%)
Updated Aug 6, 2025 03:06 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PMVP 1.47 -0.01(-0.68%)
Will PMVP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PMVP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PMVP
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMVP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PMVP
PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | PMVP Stock News
TD Cowen Keeps Their Buy Rating on PMV Pharmaceuticals (PMVP)
PMV Pharmaceuticals Reports Q1 2025 Financial Results
PMV Pharmaceuticals GAAP EPS of -$0.34 beats by $0.03